AbbVie leans on new treatments to forecast upbeat 2020 profit

The drugmaker expects the two treatments, Skyrizi and Rinvoq, to bring in a combined revenue of about $1.70 billion in 2020. The profit forecast excludes any impact from its $63 billion deal for Botox-maker Allergan Plc , which it expects to close in the first quarter. “The launches of Skyrizi and Rinvoq are going extremely well,” Chief Executive Officer Richard Gonzalez said in a statement. …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.